Prot# AEG35156-103: An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients with Refractory/Relapsed AML in Combination with Chemotherapy

  • Tallman, Martin Stuart (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date3/12/07 → 3/12/08

Funding

  • Aegera Therapeutics Inc. (AEG35156-103)